✦ LIBER ✦

Vorinostat Plus Bortezomib for the Treatment of Relapsed/Refractory Multiple Myeloma: A Case Series Illustrating Utility in Clinical Practice

✍ Scribed by Amitabha Mazumder; David H. Vesole; Sundar Jagannath

Book ID: 119936228
Publisher: Elsevier
Year: 2010
Tongue: English
Weight: 220 KB
Volume: 10
Category: Article
ISSN: 2152-2650
DOI: 10.3816/clml.2010.n.022

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I safety study of enzastaurin pl

A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma

✍ Irene M. Ghobrial; Nikhil C. Munshi; Brianna N. Harris; Peipei Shi; Nichole M. P 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 209 KB 👁 2 views

Assessing response rates in clinical tri

Assessing response rates in clinical trials of treatment for relapsed or refractory multiple myeloma: a study of bortezomib and thalidomide

✍ Prince, H M; Schenkel, B; Mileshkin, L 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 83 KB

Phase I/II trial assessing bendamustine

Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma

✍ Berenson, James R.; Yellin, Ori; Bessudo, Alberto; Boccia, Ralph V.; Noga, Steph 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 304 KB

Monosomy 13 in metaphase spreads is a pr

Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma

✍ Kiyota, Miki; Kobayashi, Tsutomu; Fuchida, Shinichi; Yamamoto-Sugitani, Mio; Ohs 📂 Article 📅 2012 🏛 Carden Jennings Publishing 🌐 English ⚖ 434 KB

Assessing response rates in clinical tri

Assessing response rates in clinical trials of treatment for relapsed or refractory multiple myeloma: a study of bortezomib and thalidomide by H Prince, Brad Schenkel and Linda Mileshkin

✍ Durie, B G M; Rajkumar, S V 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 50 KB

A phase I study of bortezomib in combina

A phase I study of bortezomib in combination with doxorubicin and intermediate-dose dexamethasone (iPAD therapy) for relapsed or refractory multiple myeloma

✍ Yasushi Takamatsu; Kazutaka Sunami; Hiroyuki Hata; Koji Nagafuji; Ilseung Choi; 📂 Article 📅 2010 🏛 Carden Jennings Publishing 🌐 English ⚖ 167 KB